Even as Tesla continues to rake in the cash, it remains absent from the portfolios of auto ETFs�and broader consumer discretionary funds. One huge positive for investors who have so far used�alternative energy�funds to gain exposure to the growing firm, there are a number of funds that revolve around the NASDAQ 100. Many ETFs will have to pick up Tesla when they rebalance to continue tracking their index, allowing for ETF exposure that was missing for Tesla.
Alternative energy funds such as the NASDAQ Clean Edge Green Energy Index Fund� have already seen huge growth from not only the great year green energy has enjoyed, but the added bonus of heavy Tesla weightings to their portfolios. QCLN, which specifically tracks the technology firms working on clean energy components, has returned nearly 60% since the beginning of the year and 36% in just the last 13 weeks�.
Best China Companies To Watch In Right Now: TeliaSonera AB (TLSN)
TeliaSonera AB is a Sweden-based company engaged in the provision of network access and telecommunication services to individual and business customers. The Company is organized into four business segments: the Mobile Services segment provides mobile services, which include mobile voice and data, mobile content, Wireless Local Area Network (WLAN) Hotspots, mobile broadband and Wireless Office to the consumer and enterprise markets; the Broadband Services segment provides services for connecting homes and offices, including broadband over copper, fiber and cable, television (TV), voice over Internet, home communications services, Internet Protocol- Virtual Private Network (IP-VPN)/Business Internet, leased lines and traditional telephony; the Eurasia segment comprises mobile operations in Kazakhstan, Azerbaijan, Uzbekistan, Tajikistan, Georgia, Moldova and Nepal, and the Other operations segment comprises Other Business Services, TeliaSonera Holding and Corporate functions. Advisors' Opinion:- [By Jonathan Morgan]
TeliaSonera (TLSN) slid 1.9 percent to 47.56 Swedish kronor. Solidium Oy, Finland�� equity-asset manager, sold 1.6 percent of shares in the Stockholm-based company in an accelerated book building to institutional investors, it said in a statement.
- [By Sarah Jones]
TeliaSonera AB (TLSN) lost 2.1 percent to 42.47 kronor after Sweden�� biggest phone company reported first-quarter net income of 4.11 billion kronor ($629 million), little changed from a year earlier. Analysts had predicted 4.32 billion kronor of profit, according to the average of 15 estimates compiled by Bloomberg. Sales fell 4.4 percent.
- [By Adam Ewing]
A sale would provide the shareholders with cash, while potentially strengthening DNA against larger rivals Elisa Oyj (ELI1V) and TeliaSonera AB. (TLSN) The IPO could be the biggest in Finland, home of Nokia Oyj (NOK1V) and ��ngry Birds��maker Rovio Entertainment Oy, since 2005.
- [By Stephen Kirkland]
Telecom Italia SpA jumped 8.4 percent after La Repubblica reported that Egyptian billionaire Naguib Sawiris may buy a stake in the phone company. The newspaper did not cite anyone. TeliaSonera AB (TLSN) slid 1.9 percent after Solidium Oy, Finland�� state-owned asset manager, started an accelerated book build to sell a stake in the Swedish telecommunications operator.
Best Clean Energy Companies To Buy Right Now: VolitionRX Ltd (VNRX)
VolitionRX Limited, formerly Standard Capital Corporation, incorporated on September 24, 1998, through its wholly owned subsidiary Singapore Volition Pte Limited (Volition), is a life sciences company focused on developing blood-based diagnostic tests. As of October 12, 2011, Volition was developing a range of blood-based epigenetic cancer screening tests, which will be released for research then clinical use in Europe, North America and globally. The tests will enable doctors to screen for the general presence of cancer in the body with a single blood test, and investigate, which cancer is present in many of those cancer positive patients using a panel of tests. On October 6, 2011, the Company announced the closure of the share exchange agreement with the Company. On October 6, 2011, Volition became a wholly owned subsidiary of the Company.
Volition�� HyperGenomics technology will determine specific epigenetic signatures from cancer biopsies. The HyperGenomics range of tests will be used as a second line once cancer has been diagnosed, to determine the specific subtype of disease and to help decide the most appropriate therapy. Volition is developing a non-invasive blood test for endometriosis, based on its Nucleosomics technology.
Advisors' Opinion:- [By Peter Graham]
At the end of last week, small cap stocks Senesco Technologies, Inc (OTCBB: SNTI), VolitionRX Ltd (OTCMKTS: VNRX) and Micromem Technologies Inc (OTCBB: MMTIF) were all trending upwards ��ending up 13.65%, 8.73% and 7.61%, respectively, on Friday. However, it�� a new trading week with the last two trading days for the year. So what direction will these three small caps head in for the end of this year and into next year? Here is a quick look to help you decide on a trading or investment strategy:
Best Clean Energy Companies To Buy Right Now: Ishares Gold Trust (IAU)
ishares Gold Trust (the Trust), incorporated on January 21, 2005, is to own gold transferred to the Trust in exchange for shares issued by the Trust (Shares). Each Share represents a fractional undivided beneficial interest in the net assets of the Trust. The assets of the Trust consist of gold held by the Trust�� custodian on behalf of the Trust. The sponsor of the Trust is BlackRock Asset Management International Inc. (the Sponsor). The trustee of the Trust is The Bank of New York Mellon (the Trustee) and the custodian of the Trust is JPMorgan Chase Bank, N.A., London branch (the Custodian).
The activities of the Trust are limited to issuing Baskets of Shares in exchange for the gold deposited with the Custodian as consideration; selling gold as necessary to cover the Sponsor�� fee, Trust expenses not assumed by the Sponsor and other liabilities, and delivering gold in exchange for Baskets of Shares surrendered for redemption. It does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of gold.
Advisors' Opinion:- [By Sean Williams]
The first method is by purchasing an ETF that closely tracks the underlying price of gold. The iShares Gold Trust (NYSEMKT: IAU ) and SPDR Gold Shares (NYSEMKT: GLD ) are two easy ways of buying into an ETF that holds physical gold without having to go through a physical gold dealer and taking delivery of the product. Also, both ETFs are extremely liquid, which means that you can access your money through your favorite brokerage by buying or selling anytime you need. The downside, of course, is that physical gold offers no dividend yield, so it's all about the price appreciation potential here.
- [By Quoth the Raven]
The other common way to invest is through ETFs such as iShares Gold Trust (IAU), which basically track the price of the commodity by physically purchasing bullion. The ETFs asset price reflect the price as which it trades for. If the underlying asset is silver, the ETF trades proportional to what the silver's worth.
Best Clean Energy Companies To Buy Right Now: bluebird bio Inc (BLUE)
bluebird bio, Inc., incorporated on April 16, 1992, is a clinical-stage biotechnology company, the Company is focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy. Gene therapy seeks to introduce a functional copy of the defective gene into a patient�� own cells, a process called gene transfer. Through gene transfer, a functional copy of the mutated gene is delivered to the patient�� cells, thereby correcting the underlying genetic defect that causes aberrant gene expression. As of December 31, 2012, the Company is conducting a Phase I/II clinical study in France evaluating an earlier generation of its LentiGlobin vector for the treatment of �-thalassemia major and SCD. Initial proof-of-concept data from this study were published in Nature. During the year ended December 31, 2013, the Company plans to initiate an extension of this study under a revised protocol for LentiGlobin, which the Company refers to as the HGB-205 Study. The Company also plans o initiate a second Phase I/II clinical program in the United States for LentiGlobin, which the Company refers to as the HGB-204 Study, for �-thalassemia major. In March 2013, the Company entered into a strategic collaboration with Celgene Corporation, or Celgene, to discover, develop and commercialize, disease-altering gene therapies in oncology.
Its gene therapy platform is based on viral vectors that utilize a modified, non-replicating version of the Human Immunodeficiency Virus Type 1 (HIV-1) virus, that has been stripped of all of the components required for it to self-replicate and infect additional cells. The HIV-1 virus is part of the lentivirus family of viruses, as a result of which the Company refer to its vectors as lentiviral vectors. Its lentiviral vectors are used to introduce a functional copy of a gene to the patient�� own isolated blood stem cells, called hematopoietic stem cells (HSCs), which reside in a patient�� bone marrow and are capable of differentiating int! o a wide range of cell types. HSCs are dividing cells, thus its approach allows for sustained expression of the modified gene as the Company is able to take advantage of a lifetime of replication of the gene-modified HSCs. Additionally, the Company has developed a cell-based vector manufacturing process that is both reproducible and scalable.
Adrenoleukodystrophy
Adrenoleukodystrophy is a rare X-linked, inherited, neurological disorder that is often fatal. ALD is caused by mutations in the ABCD1 gene which encodes for a protein called the ALD protein (ALDP), which plays a critical role in the breakdown and metabolism of long-chain fatty acids (VLCFA). Without functional ALDP, VLCFA accumulate in cells including neural cells in which they cause damage to the myelin sheath, a protective and insulating membrane that surrounds nerve cells in the brain. This damage can result in decreased motor coordination and function, visual and hearing disturbances, the loss of cognitive function, dementia, seizures, adrenal dysfunction and other complications, including death. ALD is divided into various sub-segments with three main phenotypes that impact brain function: CCALD (Childhood cerebral adrenoleukodystrophy, AMN (Adrenomyeloneuropathy) and ACALD (Adult Cerebral ALD).
�-thalassemia
�-thalassemia is a rare hereditary blood disorder caused by a genetic abnormality of the �-globin gene resulting in defective red blood cells (RBCs). Genetic mutations cause the absence or reduced production of the beta chains of hemoglobin, or �-globin, thereby preventing the proper formation of hemoglobin A, which normally accounts for greater than 95% of the hemoglobin in the blood of adults. Hemoglobin is an iron-containing protein in the blood that carries oxygen from the respiratory organs to the rest of the body. Hemoglobin A consists of four chains-two chains each of a-globin and �-globin. Normally existing at an approximate 1:1 ratio, genetic mutations that impair t! he produc! tion of �-globin can lead to a relative excess of a-globin, premature death of red blood cells. The clinical implications of the a-globin/�-globin imbalance are two-fold: first, patients lack sufficient RBCs and hemoglobin to effectively transport oxygen throughout the body and can become severely anemic; and second, the shortened life span and ineffective production of RBCs can lead to other complications such as splenomegaly, marrow expansion, bone deformities, and iron overload in organs.
Sickle cell disease
Sickle cell disease (SCD) is a hereditary blood disorder resulting from a mutation in the �-globin gene that causes polymerization of hemoglobin proteins and abnormal red blood cell function. The disease is characterized by anemia, vaso-occlusive pain crisis (a common complication of SCD in which there is severe pain due to obstructed blood flow in the bones, joints, lungs, liver, spleen, kidney, eye, or central nervous system), infections, stroke, overall poor life and early death in a subset of patients. Under low-oxygen conditions, which are exacerbated by the red blood cell abnormalities, the mutant hemoglobin aggregates causing the RBCs to take on a sickle shape (sickle cells), which causes them to aggregate and obstruct small blood vessels, thereby restricting blood flow to organs resulting in pain, cell death and organ damage. If oxygen levels are restored, the hemoglobin can disaggregate and the RBCs return to their normal shape, but over time, the sickling damages the cell membrane and the cells fail to return to the normal shape even in high-oxygen conditions.
Advisors' Opinion:- [By Garrett Cook]
Bluebird Bio (NASDAQ: BLUE) shares shot up 33.61 percent to $34.86 following the presentation of positive data on LentiGlobin BB305 at the European Hematology Association (EHA).
- [By David Williamson]
In this video, health-care analyst David Williamson takes a look at the tremendous success of the�Bluebird Bio (NASDAQ: BLUE ) �IPO. The company increased the size of its initial public offering, and priced shares at $17 -- above the top end of its range -- but that still couldn't contain investor appetite for this stock. Shares shot up 50% on the opening day of trading, and have remained there.
- [By Garrett Cook]
Bluebird Bio (NASDAQ: BLUE) shares shot up 34.74 percent to $35.15 following the presentation of positive data on LentiGlobin BB305 at the European Hematology Association (EHA).
- [By Jay Silverman]
Some of the biggest leaders in that field, and there have been dozens in fields, if not more this year, such as Bluebird (BLUE) and Stemline Therapeutics (STML) and have all pulled back to significantly lower levels; even below, in Bluebird's case, the price that had actually opened up as an IPO, even though it's above its IPO price.
Best Clean Energy Companies To Buy Right Now: PowerShares International Dividend Achievers Portfolio (PID)
PowerShares International Dividend Achievers Portfolio (the Fund) seeks to replicate, before fees and expenses, the International Dividend Achievers Index (the Index). The Fund invests in sectors, including financials, utilities, consumer staples, commercial banks, insurance, utilities and information technology. PowerShares Capital Management LLC is the adviser of the Fund.
The Index seeks to identify an international group of American Depository Receipts that have qualified as International Dividend Achievers. The Index is designed to track the performance of dividend paying American Depository Receipts and non-United States common or ordinary stocks trading on the NYSE, NADDAQ or AMEX.
Advisors' Opinion:- [By Carlton Delfeld]
Second, add to the mix, one of my long-time favorite ETFs, the PowerShares International Dividend Achievers (PID).
To get into this exclusive basket, companies have to have a record of increasing dividends for five consecutive years. The United Kingdom and Canada make up 50% of its holdings with the US at only 6%.
No comments:
Post a Comment